Şunu aradınız:: učinkovinami (Slovence - İngilizce)

med učinkovinami niso
interaction not studied.

protiretrovirusnimi učinkovinami,
antiretroviral agent that requires

farmakokinetična medsebojna delovanja z drugimi učinkovinami
pharmacokinetic interactions

sočasno jemanje z drugimi antineoplazemskimi učinkovinami:
combination with other anti-neoplastic agents:

ne uporabite skupaj z učinkovinami, ki povzročajo ototoksičnost.
do not use concurrently with substances known to cause ototoxicity.

nosečnice se morajo izogibati stiku s citotoksičnimi učinkovinami.
pregnant women must avoid contact with cytostatic medicinal product.

Študije interakcij s temi učinkovinami so opravili samo pri odraslih.
interaction studies with these agents have only been performed in adults.

telavancina in mikrobiološko odpornost v primerjavi z drugimi učinkovinami prek
the mah shall continue to monitor the activity of telavancin and the microbiological resistance as compared to other agents, through the longitudinal resistance surveillance program.

zdravljenje s temi učinkovinami je povezano s pojavom sekundarnih malignomov.
treatment with these agents is associated with the occurrence of second malignancies.

uporablja se skupaj z imunosupresivnimi učinkovinami, vključno s ciklosporinom in eā
zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including t

možna je navzkrižna preobčutljivost s sulfonilsečninami, sulfonamidi in sorodnimi učinkovinami.
cross-allergenicity with sulphonylureas, sulphonamides or related substances is possible.

sodelujoči so jemali samo mitotan ali pa kombinacije mitotana z drugimi učinkovinami.
mitotane was given alone or combined with chemotherapy with various agents.

kombinacija prezista/kobicistat se ne sme uporabljati skupaj z protiretrovirusnimi učinkovinami,
cobicistat should not be used in combination with another

uporaba tmz v kombinaciji z drugimi mielosupresivnimi učinkovinami lahko poveča verjetnost mielosupresije.
use of tmz in combination with other myelosuppressive agents may increase the likelihood of myelosuppression.

ni kliničnih podatkov o varnosti in učinkovitosti bedakilina pri sočasni uporabi s protiretrovirusnimi učinkovinami.
there are no clinical data on the safety and efficacy of bedaquiline when co-administered with antiretroviral agents.

pri kombiniranju lansoprazola z zdravilnimi učinkovinami, ki jih presnavlja ta encim, je priporočena previdnost.
10 lansoprazole may give rise to increased plasma concentrations of active substances metabolised by cyp3a4.

Študije so pokazale, da je zdravilo stalevo biološko enakovredno tabletam z ločenimi zdravilnimi učinkovinami.
the studies showed that stalevo is bioequivalent to the separate tablets.

farmakoterapevtska skupina: zdravila za ušesne bolezni - kortikosteroidi v kombinaciji z antimikrobnimi učinkovinami.
pharmacotherapeutic group: otologic - corticosteroids and anti-infectives in combination.

pri sočasni uporabi rilpivirina z učinkovinami, ki zavirajo cyp3a, so opazili povečanje koncentracije rilpivirina v plazmi.
co-administration of rilpivirine and medicinal products that inhibit cyp3a has been observed to increase the plasma concentrations of rilpivirine.

zdravljenje s sorivudinom ali kemično podobnimi učinkovinami, kot je brivudin (glejte poglavje 4.5).
treatment with sorivudine or its chemically related analogues, such as brivudine (see section 4.5),